Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2024 May-Jun;18(1S Suppl 1):1-56.
doi: 10.1097/ADM.0000000000001299.

The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder

Collaborators
Practice Guideline

The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder

Clinical Guideline Committee (CGC) Members et al. J Addict Med. 2024 May-Jun.

Abstract

The American Society of Addiction Medicine/American Academy of Addiction Psychiatry (ASAM/AAAP) Clinical Practice Guideline on the Management of Stimulant Use Disorder provides guidance on evidence-based strategies for the treatment of stimulant use disorders (StUDs), stimulant intoxication, and stimulant withdrawal, as well as secondary and tertiary prevention of harms associated with stimulant use. The Clinical Guideline Committee (CGC) comprised experts from ASAM and AAAP representing a range of clinical settings and patient populations. The guideline was developed following modified GRADE methodology. The process included a systematic literature review as well as several targeted supplemental searches. The CGC utilized Evidence to Decision tables to review available evidence and rate the strength of each recommendation. The clinical practice guideline was revised based on external stakeholder review. Key takeaways included: Contingency management represents the current standard of care for treatment of StUDs; Pharmacotherapies may be utilized off-label to treat StUDs; Acute stimulant intoxication can result in life-threatening complications that should be addressed in an appropriate level of care; Secondary and tertiary prevention strategies should be used to reduce harms related to risky stimulant use.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: None

References

    1. Centers for Disease Control and Prevention. Multiple Cause of Death Data on CDC WONDER. Accessed April 23, 2023. https://wonder.cdc.gov/mcd.html
    1. US Preventive Services Task Force, Krist AH, Davidson KW, et al. Screening for unhealthy drug use: US Preventive Services Task Force recommendation statement. JAMA. 2020;323(22):2301. doi:10.1001/jama.2020.8020 - DOI - PubMed
    1. Luethi D, Liechti ME. Designer drugs: mechanism of action and adverse effects. Arch Toxicol. 2020;94(4):1085–1133. doi:10.1007/s00204-020-02693-7 - DOI - PMC - PubMed
    1. Substance Abuse and Mental Health Services Administration. Key Substance Use and Mental Health Indicators in the United States: Results from the 2018 National Survey on Drug Use and Health. (HHS Publication No. PEP19–5068, NSDUH Series H-54). Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration; 2019. https://www.samhsa.gov/data/
    1. Substance Abuse and Mental Health Services Administration. Key Substance Use and Mental Health Indicators in the United States: Results from the 2019 National Survey on Drug Use and Health. (HHS Publication No. PEP20–07-01–001, NSDUH Series H-55) Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration; 2020. https://samhsa.gov/data

Publication types

MeSH terms

Substances